Other Events ·
Nasdaq confirms Liminatus Pharma regained compliance with minimum bid price rule after 13 consecutive days above $1.00
LIMNLiminatus Pharma, Inc.
Liminatus Pharma, Inc. regained compliance with Nasdaq's minimum bid price rule after the exchange confirmed its stock closed above $1.00 for 13 consecutive trading days from August 21 to September 9, 2026. This resolution follows a transfer to The Nasdaq Capital Market on August 4, 2026, and a 1-for-50 reverse stock split effected on August 20, 2026. The matter is now closed with no further delisting risks associated with the bid price requirement. Liminatus Pharma operates in the biotechnology industry, developing immuno-oncology and cell therapy candidates.